Rubicon Research Ltd. has launched its initial public offering (IPO), marking a significant event in India’s capital markets this year. The IPO is a book-built issue of ₹1,377.50 crore, structured as a combination of a fresh issue and an offer for sale (OFS). The fresh issue consists of 1.03 crore shares aggregating ₹500.00 crore, while the OFS comprises 1.81 crore shares aggregating ₹877.50 crore, allowing existing shareholders to partially divest their holdings.

The IPO opened for subscription on October 9, 2025, and will close on October 13, 2025. Investors can apply through both BSE and NSE platforms, with the allotment expected on October 14, 2025. The tentative listing date is set as October 16, 2025, subject to regulatory approvals.

The price band for the IPO has been fixed between ₹461 to ₹485 per share. Investors must comply with minimum lot sizes when applying. For retail investors, the minimum application is 30 shares, requiring an investment of ₹14,550 based on the upper price band. Small non-institutional investors (sNII) can apply for 14 lots (420 shares) amounting to ₹2,03,700, while big non-institutional investors (bNII) can apply for 69 lots (2,070 shares) totaling ₹10,03,950.

The IPO is expected to attract investors due to Rubicon Research’s strong positioning in the pharmaceutical and specialty chemicals sectors, with a proven track record of research and development capabilities. Analysts note that the fresh issue component will help the company raise funds for expansion, while the OFS allows existing shareholders to monetize part of their investments, providing liquidity to the market.

Investors participating in the Rubicon Research IPO are advised to carefully consider the subscription window, lot sizes, and pricing details. The IPO is part of a larger trend of robust IPO activity in India in 2025, particularly in companies with a strong research and development focus in the healthcare and specialty chemicals industries.

The IPO offers an opportunity for investors to gain exposure to a fast-growing company with strong fundamentals and growth potential. With allotment expected on October 14, 2025, and tentative listing on October 16, market participants will monitor first-day trading performance on both BSE and NSE.

In conclusion, the Rubicon Research Ltd. IPO of ₹1,377.50 crore, combining a fresh issue and an OFS, presents a significant investment opportunity for both retail and institutional investors. With a price band of ₹461–₹485, minimum retail investment of ₹14,550, and allotment and listing dates set for October 14 and 16, 2025, investors should carefully consider lot sizes, investment amounts, and market conditions before applying. The IPO underscores Rubicon Research’s growth potential and strong market presence, making it a key event in India’s IPO calendar this year.

Join our Telegram Channel for Latest News and Regular Updates.

Start your Mutual Fund Journey  by Opening Free Account in Asset Plus.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.